{"id":596,"date":"2023-09-17T16:18:00","date_gmt":"2023-09-17T16:18:00","guid":{"rendered":"https:\/\/www2.isep.ipp.pt\/icmasc\/?page_id=596"},"modified":"2024-03-02T20:59:46","modified_gmt":"2024-03-02T20:59:46","slug":"clar","status":"publish","type":"page","link":"https:\/\/www2.isep.ipp.pt\/icmasc\/?page_id=596","title":{"rendered":"Clara Ionescu"},"content":{"rendered":"\n
\"\"
Ghent University, Belgium<\/figcaption><\/figure>\n\n\n\n

Title: <\/strong>Measuring and Evaluating BMI Dependent Drug\u00a0Dynamic Response\u00a0in\u00a0Anesthetised Patients<\/p>\n\n\n\n

Abstract: <\/strong>In personalized medicine applications such as general anesthesia, an individualised pharmacokinetic (PK) model requires to move away from the classical assumption of homogeneous drug mixing in various tissue compartments in the body.\u00a0However,\u00a0the pharmacokinetic\u00a0distributions are in fact following\u00a0non-uniform distribution of uptake\/clearance time constants\u00a0for the drugs used to induce and maintain general anesthesia. This follows in the first instance from the tissue properties of muscle, fat, etc.\u00a0These\u00a0classical use of patient models assume to calculate these\u00a0constants from population based models as a function of age, gender, weight, height, lean body mass.<\/p>\n\n\n\n

Hitherto, there is no revision of these models for the incoming obesity problem in all adults as reported by WHO is expected to continually increase in coming decades, as co-morbidity correlated to increase of incidence in cardiovascular disease and type II diabetes.\u00a0When these models are used in computer based optimization algorithms to find the best drug mixture for a personalized management of anesthesia, they do not suitably match the patient at hand. It follows that\u00a0anomalous diffusion patterns affect the drug dynamic mixing and transforming to the effect site (further linked to its effect by PD pharmacodynamic models), and therefore affects the overall control system performance. As an example, a lean patient will have a faster and more homogeneous distribution of drug in the body than an obese patient. This presentation gives an overview on the opportunities to\u00a0develop sensing techniques for a framework that will correlate BMI to fat volume in such PK models. There is an opportunity to\u00a0employ fractional order models for anomalous diffusion characterization in drug accumulation and release dynamics.\u00a0An experimental setup and data analysis from fat tissue samples is used to illustrate initial steps towards a theory that would offer a revision of the classic patient models.<\/p>\n\n\n\n

Bio:<\/strong> Dr Clara Mihaela Ionescu is professor at Faculty of Engineering and Architecture, at Ghent University, Belgium since October 2016. She is a research-member of the laboratory of Dynamical Systems and Control. She holds a master degree is Automation and Applied Informatics in 2003 from Dunarea de Jos University of Galati, Romania, and a PhD degree in Biomedical Engineering from Ghent University in 2009. She was recipient of prestigious excellence scholarship for top-students going abroad from the Romanian Ministry of Research and Innovation during her master Studies at Ghent University in 2002. She was also recipient of prestigious excellent post-doctoral scholarship of Flemish Research Foundation, of Belgium for 6 years, from 2011 – 2017.<\/p>\n\n\n\n

She is an ERC Consolidator Grant fellow: AMICAS, Adaptive Multi-Drug Infusion Control System for General Anesthesia during Major Surgery.<\/p>\n\n\n\n

<< BACK<\/a><\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"

Title: Measuring and Evaluating BMI Dependent Drug\u00a0Dynamic Response\u00a0in\u00a0Anesthetised Patients Abstract: In personalized medicine applications such as general anesthesia, an individualised pharmacokinetic (PK) model requires to move away from the classical assumption of homogeneous drug mixing in various tissue compartments in the body.\u00a0However,\u00a0the pharmacokinetic\u00a0distributions are in fact following\u00a0non-uniform distribution of uptake\/clearance time constants\u00a0for the drugs used … <\/p>\n","protected":false},"author":2,"featured_media":0,"parent":242,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-596","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/www2.isep.ipp.pt\/icmasc\/index.php?rest_route=\/wp\/v2\/pages\/596","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www2.isep.ipp.pt\/icmasc\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www2.isep.ipp.pt\/icmasc\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www2.isep.ipp.pt\/icmasc\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www2.isep.ipp.pt\/icmasc\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=596"}],"version-history":[{"count":7,"href":"https:\/\/www2.isep.ipp.pt\/icmasc\/index.php?rest_route=\/wp\/v2\/pages\/596\/revisions"}],"predecessor-version":[{"id":1017,"href":"https:\/\/www2.isep.ipp.pt\/icmasc\/index.php?rest_route=\/wp\/v2\/pages\/596\/revisions\/1017"}],"up":[{"embeddable":true,"href":"https:\/\/www2.isep.ipp.pt\/icmasc\/index.php?rest_route=\/wp\/v2\/pages\/242"}],"wp:attachment":[{"href":"https:\/\/www2.isep.ipp.pt\/icmasc\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=596"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}